National Academies Press: OpenBook
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

GENERATING EVIDENCE FOR GENOMIC DIAGNOSTIC TEST DEVELOPMENT

WORKSHOP SUMMARY

Theresa Wizemann and Adam C. Berger, Rapporteurs

Roundtable on Translating Genomic-Based Research for Health

Board on Health Sciences Policy

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS

Washington, D.C.
www.nap.edu

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

THE NATIONAL ACADEMIES PRESS
500 Fifth Street, N.W.
Washington, DC 20001

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

This project was supported by contracts between the National Academy of Sciences and the American College of Medical Genetics (unnumbered contract); American Medical Association (unnumbered contract); American Nurses Association (unnumbered contract); Blue Cross and Blue Shield Association (unnumbered contract); Centers for Disease Control and Prevention (Contract No. 200-2005-13434); College of American Pathologists (unnumbered contract); Department of the Air Force (Contract No. FA7014-10-P-0072); Department of Veterans Affairs (Contract No. V101(93) P-2238); Eli Lilly and Company (Contract No. LRL-0028-07); Genetic Alliance (unnumbered contract); Health Resources and Services Administration; Johnson & Johnson (unnumbered contract); Kaiser Permanente (unnumbered contract); National Cancer Institute (Contract No. N01-OD-4-2139, TO#189); National Heart, Lung, and Blood Institute (Contract No. N01-OD-4-2139, TO#189); National Human Genome Research Institute (Contract No. N01-OD-4-2139, TO#189); National Society of Genetic Counselors (unnumbered contract); and Pfizer Inc. (Contract No. 140-N-1818071). Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the views of the organizations or agencies that provided support for the project.

International Standard Book Number-13: 978-0-309-21104-8

International Standard Book Number-10: 0-309-21104-2

Additional copies of this report are available from

The National Academies Press,

500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet, http://www.nap.edu.

For more information about the Institute of Medicine, visit the IOM home page at www.iom.edu.

Copyright 2011 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.

Suggested citation: IOM (Institute of Medicine). 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

“Knowing is not enough; we must apply.

Willing is not enough; we must do.”

—Goethe

INSTITUTE OF MEDICINE
OF THE NATIONAL ACADEMIES


Advising the Nation. Improving Health.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine


The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.


The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Charles Vest is president of the National Academy of Engineering.


The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.


The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Charles Vest are chair and vice chair, respectively, of the National Research Council.


www.national-academies.org

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

PLANNING COMMITTEE1

NAOMI ARONSON, Executive Director,

Technology Evaluation Center, Blue Cross and Blue Shield Association, Chicago, IL

ANDREW FREEDMAN, Branch Chief,

Clinical and Translational Epidemiology Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD

ROGER D. KLEIN, Director,

Molecular Oncology Laboratory at BloodCenter of Wisconsin;

Clinical Assistant Professor of Pathology,

Medical College of Wisconsin, Milwaukee

DEBRA LEONARD, Professor and Vice Chair for Laboratory Medicine, Director of the Clinical Laboratories, and Director of the Pathology Residency Training Program,

Weill Cornell Medical Center of Cornell University, New York, NY

ELIZABETH MANSFIELD, Director of the Personalized Medicine Staff,

Office of In Vitro Diagnostic Device Evaluation and Safety in the Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD

ROBERT McCORMACK, Director for Technology Assessment, Ortho-Clinical Diagnostics; Vice President of Scientific and Medical Affairs,

Veridex, LLC, Raritan, NJ

ROBERT NUSSBAUM, Chief of the Division of Medical Genetics,

Department of Medicine, Institute of Human Genetics, San Francisco, CA

KIM POPOVITS, President and Chief Executive Officer,

Genomic Health, Redwood City, CA

RONALD PRZYGODZKI, Associate Director for Genomic Medicine, Acting Director of Biomedical Laboratory Research and Development,

Office of Research and Development, Department of Veterans Affairs, Washington, DC

ALLEN ROSES, President and Chief Operating Officer,

Cabernet, Shiraz and Zinfandel Pharmaceuticals;

Jefferson–Pilot Professor of Neurobiology and Genetics, Professor of Medicine (Neurology), Director of the Deane Drug Discovery Institute; Senior Scholar at the Fuqua School of Business,

Duke University, Durham, NC

DANIEL WATTENDORF, Deputy Chief,

Medical Innovations, Department of the Air Force;

Program Manager,

DARPA/Defense Sciences Office, Arlington, VA

1

Institute of Medicine planning committees are solely responsible for organizing the workshop, identifying topics, and choosing speakers. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

IOM Staff

ADAM C. BERGER, Project Director

CLAIRE F. GIAMMARIA, Research Associate

TONIA E. DICKERSON, Senior Program Assistant

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

ROUNDTABLE ON TRANSLATING GENOMIC-BASED RESEARCH FOR HEALTH1

WYLIE BURKE (Chair), Professor and Chair,

Department of Bioethics and Humanities, University of Washington, Seattle

NAOMI ARONSON, Executive Director,

Technology Evaluation Center, Blue Cross and Blue Shield Association, Chicago, IL

BRUCE BLUMBERG, Co-Chief of Medical Genetics,

Kaiser Permanente, and

Institutional Director of Graduate Medical Education,

Northern California Kaiser Permanente, The Permanente Medical Group, Oakland, CA

DENISE E. BONDS, Medical Officer,

Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD

C. THOMAS CASKEY, Director and Chief Executive Officer of the Brown Foundation Institute of Molecular Medicine, the George & Cynthia Mitchell Distinguished Chair in Neurosciences, and Executive Vice President of Molecular Medicine and Genetics,

University of Texas Health Science Center at Houston

STEPHEN ECK, Vice President,

Translational Medicine and Pharmacogenomics, Eli Lilly and Company, Indianapolis, IN

W. GREGORY FEERO, Special Advisor to the Director for Genomic Medicine,

National Human Genome Research Institute, Bethesda, MD

ANDREW N. FREEDMAN, Branch Chief,

Clinical and Translational Epidemiology Branch, Epidemiology and Genetics Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD

GEOFFREY GINSBURG, Director,

Center for Genomic Medicine, Institute for Genomic Sciences and Policy, Duke University, Durham, NC

SHARON KARDIA, Professor and Chair of Epidemiology; Director,

Public Health Genetics Program;

Director,

Life Science and Society Program;

Co-Director,

Center for Genomics & Public Health, University of Michigan School of Public Health, Ann Arbor

MOHAMED KHAN,

representing the American Medical Association;

Leader of Radiation Oncology,

Vancouver Cancer Centre, BC Cancer Agency, Vancouver, BC, Canada

1

Institute of Medicine Forums and Roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

MUIN KHOURY, Director,

National Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA

DEBRA LEONARD,

representing the College of American Pathologists;

Professor and Vice Chair for Laboratory Medicine, Director of the Clinical Laboratories, and Director of the Pathology Residency Training Program,

Weill Cornell Medical Center of Cornell University, New York, NY

MICHELE LLOYD-PURYEAR, Chief,

Genetic Services Branch, Health Resources and Services Administration, Rockville, MD

ELIZABETH MANSFIELD, Director of the Personalized Medicine Staff,

Office of In Vitro Diagnostic Device Evaluation and Safety in the Center for Devices and Radiological Health, Food and Drug Administration, Silver Spring, MD

GARRY NEIL, Corporate Vice President,

Corporate Office of Science and Technology, Johnson & Johnson, New Brunswick, NJ

ROBERT L. NUSSBAUM, Chief,

Division of Medical Genetics, Department of Medicine and Institute of Human Genetics, University of California–San Francisco School of Medicine

AIDAN POWER, Vice President and

Global Head of Molecular Medicine, Pfizer Inc., Groton, CT

RONALD PRZYGODZKI, Associate Director for Genomic Medicine,

Biomedical Laboratory Research and Development, Department of Veterans Affairs, Washington, DC

ALLEN D. ROSES, President and Chief Operating Officer,

Cabernet, Shiraz and Zinfandel Pharmaceuticals;

Jefferson–Pilot Professor of Neurobiology and Genetics, Professor of Medicine (Neurology); Director,

Deane Drug Discovery Institute;

Senior Scholar,

Fuqua School of Business, R. David Thomas Executive Training Center, Duke University, Durham, NC

KEVIN A. SCHULMAN, Professor of Medicine and Business Administration; Director,

Center for Clinical and Genetic Economics;

Associate Director,

Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC

SHARON TERRY, President and Chief Executive Officer,

Genetic Alliance, Washington, DC

MARTHA TURNER, Assistant Director,

American Nurses Association Center for Ethics and Human Rights, Silver Spring, MD

MICHAEL S. WATSON, Executive Director,

American College of Medical Genetics, Bethesda, MD

DANIEL WATTENDORF, Deputy Chief,

Medical Innovations, Department of the Air Force;

Program Manager,

DARPA/Defense Sciences Office, Arlington, VA

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

CATHERINE A. WICKLUND, Past President, National Society of Genetic Counselors; Director,

Graduate Program in Genetic Counseling;

Assistant Professor,

Department of Obstetrics and Gynecology, Northwestern University, Chicago, IL

IOM Staff

ADAM C. BERGER, Project Director

CLAIRE F. GIAMMARIA, Research Associate

TONIA E. DICKERSON, Senior Program Assistant

ANDREW POPE, Director,

Board on Health Sciences Policy

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Reviewers

This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the process. We wish to thank the following individuals for their review of this report:

Margaret Piper, Director of Genomics Resources, Blue Cross and Blue Shield Association Technology Evaluation Center, Atlanta, GA

Jeffrey Roche, Medical Officer, Office of Clinical Standards and Quality, Center for Medicare and Medicaid Services, Baltimore, MD

Steven Shak, Chief Medical Officer, Genomic Health, Inc., Redwood City, CA

Sean Tunis, Director, Center for Medical Technology Policy, Baltimore, MD

Although the reviewers listed above have provided many constructive comments and suggestions, they did not endorse the final draft of the report before its release. The review of this report was overseen by Harold J.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Fallon, Dean Emeritus of the University of Alabama at Birmingham School of Medicine. Appointed by the Institute of Medicine, he was responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this report rests entirely with the author and the institution.

Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Acknowledgments

The support of the sponsors of the Institute of Medicine Roundtable on Translating Genomic-Based Research for Health was crucial to the planning and conduct of the workshop “Generating Evidence for Genomic Diagnostic Test Development.” Federal sponsors are the Department of the Air Force; Centers for Disease Control and Prevention; Health Resources and Services Administration; National Cancer Institute; National Heart, Lung, and Blood Institute; National Human Genome Research Institute; and the Department of Veterans Affairs. Non-federal sponsorship was provided by the American College of Medical Genetics, the American Medical Association, the American Nurses Association, Blue Cross and Blue Shield Association, the College of American Pathologists, Eli Lilly and Company, Genetic Alliance, Johnson & Johnson, Kaiser Permanente, the National Society of Genetic Counselors, and Pfizer Inc.

The Roundtable wishes to express its gratitude to the expert speakers whose presentations helped outline the challenges and opportunities in generating evidence for genomic diagnostic tests. The Roundtable also wishes to thank the members of the planning committee for their work in developing an excellent workshop agenda.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page xvii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Tables, Figures, and Boxes

TABLES

1-1

 

Evidence-Based Review of Select Genomic Tests,

 

3

2-1

 

Oncotype Dx Reclassification of Patients,

 

13

3-1

 

Classic Randomized Controlled Trials (RCTs) Versus Practical Clinical Trials (PCTs),

 

28

3-2

 

Summary of Ontario Field Evaluations,

 

36

FIGURES

2-1

 

Sample analytic framework,

 

16

2-2

 

Breast cancer mortality rates from 1950-2003 and the effect of screening and adjuvant therapy,

 

20

3-1

 

Pharmacogenomic trial designs, including retrospective, prospective stratified, and prospective screened,

 

26

3-2

 

Hypothetical genotype-guided versus usual care scenario to measure smoking cessation rates using varenicline or patch,

 

30

3-3

 

Prospective stratified RCT scheme,

 

30

3-4

 

MAS- and OHTAC-associated structures and linkages,

 

34

Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

BOXES

1-1

 

Speakers’ Perspectives on Barriers to the Collection of Clinical Validity and Utility Data for Genomic Diagnostic Tests,

 

4

2-1

 

Stakeholder Perspectives on Evidence,

 

6

2-2

 

Challenges to Establishing Analytical and Clinical Validity of Diagnostics,

 

8

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

Abbreviations and Acronyms

ACCE analytic validity, clinical validity, clinical utility, and associated ethical, legal, and social implications model

AHRQ Agency for Healthcare Research and Quality

ASCO American Society of Clinical Oncology

CAP College of American Pathologists

CDC Centers for Disease Control and Prevention

CDRH Center for Devices and Radiological Health (FDA)

CLIA Clinical Laboratory Improvement Amendments

EGAPP Evaluation of Genomic Applications in Practice and Prevention

EGFR epidermal growth factor receptor

eMERGE Electronic Medical Records and Genomics

ER estrogen receptor

FDA U.S. Food and Drug Administration

GAPPNet Genomic Applications in Practice and Prevention Network

GWAS genome-wide association study

HMO health maintenance organization

IHC immunohistochemistry

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×

LOE level of evidence

MAQC microarray quality control

MAS Medical Advisory Secretariat

MSI microsatellite instability

NCI National Cancer Institute (NIH)

NHGRI National Human Genome Research Institute

NIDDK National Institute of Diabetes and Digestive and Kidney Diseases (NIH)

NIH National Institutes of Health

OHTAC Ontario Health Technology Advisory Committee

PET positron emission tomography

PSA prostate-specific antigen

RCT randomized controlled trial

SSRI selective serotonin reuptake inhibitor

TEC Technology Evaluation Center (Blue Cross and Blue Shield Association)

Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R1
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R2
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R3
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R4
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R5
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R6
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R8
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R9
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R10
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R11
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R13
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R14
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R15
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R16
Page xvii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R17
Page xviii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R18
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R19
Suggested Citation:"Front Matter." Institute of Medicine. 2011. Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/13133.
×
Page R20
Next: 1 Introduction »
Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person's response to certain drugs, estimate the risk of developing Alzheimer's disease, and make other predictions based on known links between genes and diseases. However, genetic tests have yet to become a routine part of medical care, in part because there is not enough evidence to show they help improve patients' health.

The Institute of Medicine (IOM) held a workshop to explore how researchers can gather better evidence more efficiently on the clinical utility of genetic tests. Generating Evidence for Genomic Diagnostic Test Development compares the evidence that is required for decisions regarding clearance, use, and reimbursement, to the evidence that is currently generated. The report also addresses innovative and efficient ways to generate high-quality evidence, as well as barriers to generating this evidence.

Generating Evidence for Genomic Diagnostic Test Development contains information that will be of great value to regulators and policymakers, payers, health-care providers, researchers, funders, and evidence-based review groups.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!